Welcome to our dedicated page for Bolt Biotherapeutics SEC filings (Ticker: BOLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bolt Biotherapeutics SEC filings document the company’s public-company governance, financial-results reporting, and clinical-stage oncology disclosures. Recent Form 8-K reports furnish quarterly and annual results and business updates for BDC-4182 and the Boltbody™ ISAC platform, while proxy materials describe director elections, auditor ratification, and stockholder meeting mechanics.
The filing record also includes emerging growth company status, restructuring disclosures under exit or disposal activity rules, estimated severance and benefit costs, and updates on pipeline and capital-preservation measures. These filings frame Bolt’s governance procedures, operating expense controls, reporting status, and development-stage business disclosures as a Nasdaq-listed biopharmaceutical issuer.
Bolt Biotherapeutics files its annual report outlining a focused immuno-oncology strategy built around its Boltbody ISAC platform. The company is prioritizing clinical development of BDC-4182, a claudin 18.2-targeting ISAC in a first-in-human Phase 1 trial for gastric/gastroesophageal junction cancer, while other pipeline programs are on hold pending funding or partnerships.
Bolt highlights collaborations with Toray, Genmab and Innovent, an exclusive license to core ISAC technology from Stanford, and a patent estate expected to run into the 2040s. As of June 30, 2025, non-affiliate common stock held a market value of about $7.3 million, and as of March 6, 2026, 1,921,567 shares of common stock were outstanding. The company reports only 23 employees and emphasizes that it has a limited operating history, significant accumulated losses, substantial future funding needs, and numerous clinical, regulatory, manufacturing, competition, reimbursement and macroeconomic risks that could affect its ability to commercialize any product candidates and maintain its stock price.
Bolt Biotherapeutics reported fourth-quarter and full-year 2025 results showing sharply lower operating losses and a more focused pipeline. Full-year loss from operations narrowed to $36.1 million from $73.0 million in 2024 as research and development and general and administrative costs were reduced following restructuring.
Collaboration revenue was $7.7 million for 2025, flat with 2024, with $2.5 million recognized in the fourth quarter. Net loss improved to $33.4 million from $63.1 million a year earlier. Cash, cash equivalents and marketable securities totaled $31.8 million as of December 31, 2025, which the company expects will fund key milestones and operations into 2027.
The lead Boltbody™ ISAC candidate, BDC-4182 targeting claudin 18.2, is in a Phase 1 dose-escalation trial in gastric and gastroesophageal cancers, with initial clinical data expected in the third quarter of 2026. Two additional ISAC programs targeting CEA and PD-L1 remain on hold pending partnering or funding.
Bolt Biotherapeutics, Inc. received an amended Schedule 13D showing updated ownership by Nan Fung- and Pivotal-affiliated entities in its common stock. Nan Fung Group Holdings Limited reports beneficial ownership of 87,486 shares, or 4.6% of the common stock, with other related entities holding smaller stakes.
The reported percentages are calculated using 1,919,441 outstanding shares of common stock, as referenced from the company’s Form 10-Q filed on November 12, 2025. The filing states that on February 26, 2026, the reporting persons ceased to be beneficial owners of more than five percent of Bolt’s common stock. In addition, Mr. Kam Chung Leung directly owns 8,684 shares of common stock.
Nal Fung–affiliated and Pivotal bioVenture entities filed Amendment No. 3 to report their beneficial ownership of Bolt Biotherapeutics common stock. Nan Fung Group Holdings Limited reports beneficial ownership of 128,119 shares, representing 6.7% of the common stock.
Several related entities, including Pivotal bioVenture Partners Fund I, L.P., report shared voting and dispositive power over 78,445 shares, or 4.1% of the class, while other Nan Fung life sciences entities report additional stakes ranging from 0.3% to 6.4%. The percentages are calculated against 1,919,441 shares outstanding as of the issuer’s Form 10‑Q filed November 12, 2025. The filing also notes that Mr. Kam Chung Leung directly owns 8,684 shares and that, except as described in an attached schedule, no reporting person has traded the stock in the past sixty days.
Vivo Panda Fund, L.P., an investor in Bolt Biotherapeutics, Inc., reports beneficial ownership of 72,414 shares of Bolt common stock, representing 3.8% of the class, in this amended Schedule 13G. The percentage is based on 1,919,441 shares outstanding as of November 5, 2025, as disclosed in Bolt’s Form 10-Q. Other affiliated Vivo Capital funds now report 0 shares and 0% ownership. The filers certify the shares are not held to change or influence control of Bolt.
Bolt Biotherapeutics President, CEO and CFO William P. Quinn reported two transactions in company securities. On December 5, 2025, he purchased 125 shares of common stock at $4.607 per share under the Employee Stock Purchase Plan, bringing his directly held common stock to 2,313 shares.
On January 28, 2026, he was granted an employee stock option for 20,000 shares of common stock at an exercise price of $6.71 per share, expiring on January 27, 2036. The option vests in 36 equal monthly installments, with 1/36th of the shares vesting after each month of continuous service following January 1, 2026.
Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer, Yonehiro Grant, received an employee stock option grant. On January 28, 2026, Grant was awarded options to purchase 10,000 shares of Bolt common stock at an exercise price of $6.71 per share, expiring January 27, 2036.
The options vest over time, so long as Grant continues providing services to Bolt. Starting from January 1, 2026, 1/36 of the options vest after each completed month of continuous service, until all 10,000 options are fully vested.
Bolt Biotherapeutics officer reports small share purchase and new option grant. Senior VP, Finance and PAO Sarah Nemec bought 125 shares of common stock on 12/05/2025 at $4.607 per share under the company’s Employee Stock Purchase Plan, bringing her direct holdings to 1,415 shares.
On 01/28/2026 she received an employee stock option for 8,000 shares at a $6.71 exercise price. This option is scheduled to vest in equal monthly installments, with 1/36 of the shares vesting after each month of continuous service following January 1, 2026, and expires on January 27, 2036.
A director of Bolt Biotherapeutics, Inc. reported cancelling previously granted director stock options and receiving new options with lower exercise prices.
On December 12, 2025, the director received new options to buy 2,500, 849, 1,000 and 1,100 shares of common stock at an exercise price of $5.44 per share, with expiration dates between September 2, 2034 and May 26, 2035. In each case, options with higher exercise prices ranging from $6.40 to $13.596 for the same number of shares and similar expiration dates were cancelled in exchange for the new options, some of which are fully vested and others subject to monthly or time-based vesting and full vesting upon a change in control.
Bolt Biotherapeutics, Inc. director reported stock option transactions dated 12/12/2025. The Form 4 shows several director stock options on common stock being canceled and replaced with new options that have a lower exercise price, as described in the footnotes.
New director stock options with exercise prices such as $5.44 per share cover grants expiring on 12/13/2031, 03/23/2032, 06/09/2032, 06/11/2033, 06/11/2034 and 05/26/2035. One option is fully vested and exercisable, while another for 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately before the next annual meeting of stockholders, and will vest in full upon a change in control, subject to the director’s continuous service.